APA (7th ed.) Citation

R, M., J, Z., MX, Z., Y, L., Y, Y., LR, W., . . . YQ, S. (2026). Survival benefit of allogeneic HSCT in CMML patients during the molecular stratification era. Cancer letters, 649, 218489. https://doi.org/10.1016/j.canlet.2026.218489

Chicago Style (17th ed.) Citation

R, Ma, et al. "Survival Benefit of Allogeneic HSCT in CMML Patients During the Molecular Stratification Era." Cancer Letters 649 (2026): 218489. https://doi.org/10.1016/j.canlet.2026.218489.

MLA (9th ed.) Citation

R, Ma, et al. "Survival Benefit of Allogeneic HSCT in CMML Patients During the Molecular Stratification Era." Cancer Letters, vol. 649, 2026, p. 218489, https://doi.org/10.1016/j.canlet.2026.218489.